Articles scientifiques

A gene signature to predict high tumour-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple negative breast cancer.

Auteurs : Criscitiello C, Bayar MA, Curigliano G, Symmans FW, Desmedt C, Bonnefoi H, Sinn B, Pruneri G, Vicier C, Pierga JY, Denkert C, Loibl S, Sotiriou C, Michiels S, André F
Année : 2018
Journal : Ann Oncol
Volume : 29(1)
Pages : 162-169

CDK4/6 inhibitors as neoadjuvant treatment in breast cancer - what can we learn?

Auteurs : Brandão M, Ignatiadis M
Année : 2018
Journal : Ann Oncol
Volume : 29(12)
Pages : 2274-2278

Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients.

Auteurs : Lambertini M, Goldrat O, Ferreira AR, Dechene J, Azim HA Jr, Desir J, Delbaere A, Tkint de Roodenbeke D, de Azambuja E, Ignatiadis M, Demeestere I
Année : 2018
Journal : Ann Oncol
Volume : 29(1)
Pages : 237-243

Feasibility of developing reliable gene expression modules from FFPE derived RNA profiled on Affymetrix arrays.

Auteurs : Jose V, Fumagalli D, Rothé F, Majjaj S, Loi S, Michiels S, Sotiriou C
Année : 2018
Journal : PLoS One
Volume : 13
Pages : e0203346

Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status.

Auteurs : Lambertini M, Kroman N, Ameye L, Cordoba O, Pinto A, Benedetti G, Jensen MB, Gelber S, Del Grande M, Ignatiadis M, de Azambuja E, Paesmans M, Peccatori FA, Azim HA Jr
Année : 2018
Journal : J Natl Cancer Inst
Volume : 110(4)
Pages : 426-429

The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients.

Auteurs : Lambertini M, Di Maio M, Pagani O, Curigliano G, Poggio F, Del Mastro L, Paluch-Shimon S, Loibl S, Partridge AH, Demeestere I, Azim HA Jr, Peccatori FA
Année : 2018
Journal : Breast
Volume : 42
Pages : 41-49

Breast cancer diagnosed during pregnancy is associated with enrichment of non-silent mutations, mismatch repair deficiency signature and mucin mutations.

Auteurs : Nguyen B, Venet D, Azim HA Jr, Brown D, Desmedt C, Lambertini M, Majjaj S, Pruneri G, Peccatori F, Piccart-Gebhart M, Rothé F, Sotiriou C
Année : 2018
Journal : NPJ Breast Cancer
Volume : 4
Pages : 23

Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning.

Auteurs : Klauschen F, Müller KR, Binder A, Bockmayr M, Hägele M, Seegerer P, Wienert S, Pruneri G, de Maria S, Badve S, Michiels S, Nielsen TO, Adams S, Savas P, Symmans F, Willis S, Gruosso T, Park M, Haibe-Kains B, Gallas B, Thompson AM, Cree I, Sotiriou C, Solinas C, Preusser M, Hewitt SM, Rimm D, Viale G, Loi S, Loibl S, Salgado R, Denkert C
Année : 2018
Journal : Semin Cancer Biol
Volume : 52
Pages : 151-157

Immunity drives TET1 regulation in cancer through NF-?B.

Auteurs : Collignon E, Canale A, Al Wardi C, Bizet M, Calonne E, Dedeurwaerder S, Garaud S, Naveaux C, Barham W, Wilson A, Bouchat S, Hubert P, Van Lint C, Yull F, Sotiriou C, Willard-Gallo K, Noel A, Fuks F
Année : 2018
Journal : Sci Adv
Volume : 4
Pages : eaap7309

Trastuzumab versus observation for HER2 non amplified early breast cancer with Circulating Tumor Cells (EORTC 90091-10093, BIG 1-12, Treat CTC): A randomized phase 2 trial.

Auteurs : Ignatiadis M, Litière S, Rothé F, Riethdorf S, Proudhon C, Fehm T, Aalders K, Forstbauer H, Fasching P, Brain E, Vuylsteke P, Guardiola E, Lorenz R, Pantel K, Tryfonidis K, Janni W, Piccart-Gebhart M, Sotiriou C, Rack B, Pierga JY
Année : 2018
Journal : Ann Oncol
Volume : 29(8)
Pages : 1777-1783

Observational study on the prognostic value of testosterone and adiposity in postmenopausal estrogen receptor positive breast cancer patients.

Auteurs : Venturelli E, Orenti A, Fabricio ASC, Garrone G, Agresti R, Paolini B, Bonini C, Gion M, Berrino F, Desmedt C, Coradini D, Biganzoli E
Année : 2018
Journal : BMC Cancer
Volume : 18
Pages : 651

Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial.

Auteurs : Powles RL, Redmond D, Sotiriou C, Loi S, Fumagalli D, Nuciforo P, Harbeck N, de Azambuja E, Sarp S, Di Cosimo S, Huober J, Baselga J, Piccart-Gebhart M, Elemento O, Pusztai L, Hatzis C
Année : 2018
Journal : JAMA Oncol
Volume : 4
Pages : e181564

Treatment of advanced HER2-positive breast cancer: 2018 and beyond.

Auteurs : Pondé N, Brandão M, El-Hachem G, Werbrouck E, Piccart-Gebhart M
Année : 2018
Journal : Cancer Treat Rev
Volume : 67
Pages : 10-20

Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects.

Auteurs : Brandão M, Pondé NF, Poggio F, Kotecki N, Salis M, Lambertini M, de Azambuja E
Année : 2018
Journal : Expert Rev Anticancer Ther
Volume : 18
Pages : 629-649

Circulating tumor DNA in early response assessment and monitoring of advanced colorectal cancer treated with a multi-kinase inhibitor.

Auteurs : Vandeputte C, Kehagias P, El Housni H, Ameye L, Laes JF, Desmedt C, Sotiriou C, Deleporte A, Puleo F, Geboes K, Delaunoit T, Demolin G, Peeters M, DHondt L, Janssens J, Carrasco J, Marechal R, Gomez Galdon M, Heimann P, Paesmans M, Flamen P, Hendlisz A
Année : 2018
Journal : Oncotarget
Volume : 9
Pages : 17756-17769

Breast cancer and pregnancy-related issues.

Auteurs : Lambertini M, Nguyen B, Viglietti G, Martel S, de Azambuja E
Année : 2018
Journal : Belgian J Medical Oncology
Volume : 11(1)
Pages : 9-14

Potential Benefit of Intra-operative Administration of Ketorolac on Breast Cancer Recurrence According to the Patient's Body Mass Index.

Auteurs : Desmedt C, Demicheli R, Fornili M, Bachir I, Duca M, Viglietti G, Berlière M, Piccart-Gebhart M, Sotiriou C, Sosnowski M, Forget P, Biganzoli E
Année : 2018
Journal : J Natl Cancer Inst
Volume : 110(10)
Pages : 1115-1122

PUBLISHED ERRATUM (2016): PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.

Auteurs : Loibl S, Majewski I, Guarneri V, Nekljudova V, Holmes E, Bria E, Denkert C, Schem C, Sotiriou C, Loi S, Untch M, Conte P, Bernards R, Piccart-Gebhart M, Von Minckwitz G, Baselga J
Année : 2018
Journal : Ann Oncol
Volume : 29
Pages : 2151

erratum :Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.

Auteurs : Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Peña L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm DL, Baselga J, Pusztai L
Année : 2018
Journal : Ann Oncol
Volume : 29
Pages : 2152

18FDG-PET/CT and molecular markers to predict response to neoadjuvant chemotherapy and outcome in HER2-negative advanced luminal breast cancers patients.

Auteurs : de Cremoux P, Biard L, Poirot B, Bertheau P, Teixeira L, Lehmann-Che J, Bouhidel FA, Merlet P, Espié M, Resche-Rigon M, Sotiriou C, Groheux D
Année : 2018
Journal : Oncotarget
Volume : 9
Pages : 16343-16353